Preliminary efficacy of bevacizumab with first-line folfox, xelox, folfiri and fluoropyrimidines for mCRC: First BEAT trial

被引：8

作者：

Berry, S. ^{[1
]}

Cunningham, D. ^{[2
]}

Michael, M. ^{[3
]}

Kretzschmar, A. ^{[4
]}

Rivera, F. ^{[5
]}

DiBartolomeo, M. ^{[6
]}

Mazier, M. ^{[7
]}

Lutiger, B. ^{[8
]}

Van Cutsem, E. ^{[9
]}

机构：

[1] Sunnybrook Reg Canc Ctr, Toronto, ON, Canada

[2] Royal Marsden Hosp, Dept Med, Sutton, Surrey, England

[3] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia

[4] HELIOS, Klinikum Berlin, Charite, Robert Rossle Klin, Berlin, Germany

[5] Hosp Marques Valdecilla, SV Oncol Med, Santander, Spain

[6] Ist Nazl Tumori, Div Med Oncol Unit 2, I-20133 Milan, Italy

[7] Dept Stat, Paris, France

[8] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[9] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium

来源：

EJC SUPPLEMENTS | 2007年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1359-6349(07)70948-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3020

引用

页码：241 / 241

页数：1